Search Results - "HENNEBELLE, Isabelle"

Journal Article

Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages

by Castells, Magali Thibault, Benoît Mery, Eliane Golzio, Muriel Pasquet, Marlene Hennebelle, Isabelle Bourin, Philippe Mirshahi, Massoud Delord, Jean Pierre Querleu, Denis Couderc, Bettina Published in Cancer letters (2012)

“...Abstract Within the microenvironment, Carcinoma-associated mesenchymal stem cells (Hospicells) are able to influence ovarian tumor development via, among...”

Journal Article

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

by Balin-Gauthier, Diane Balin-Gauthier, Diane Delord, Jean-Pierre Delord, Jean-Pierre Rochaix, Philippe Rochaix, Philippe Mallard, Valérie Mallard, Valérie Thomas, Fabienne Thomas, Fabienne Hennebelle, Isabelle Hennebelle, Isabelle Bugat, Roland Bugat, Roland Canal, Pierre Canal, Pierre Allal, Cuider Allal, Cuider Published in Cancer chemotherapy and pharmacology (01.06.2006)

“...This study aimed to assess the effect of cetuximab (C225, Erbitux®, a chimeric anti-epidermal growth factor receptor (EGFR) monoclonal antibody) in combination...”

Fulltext

Journal Article

Gene expression profiling on pre‐ and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma

by Thomas, Fabienne Delmar, Paul Vergez, Sébastien Rochaix, Philippe Hennebelle, Isabelle McLoughlin, Patricia Benlyazid, Adil Sarini, Jérôme Delord, Jean–Pierre Published in Head & neck (01.06.2013)

“...Background The purpose of our work was to identify genomic predictive markers of erlotinib response in patients with head and neck squamous cell carcinoma...”

Fulltext

Journal Article

Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report

by Laurenty, Anne-Pascale Thomas, Fabienne Chatelut, Etienne Bétrian, Sarah Le Guellec, Chantal Hennebelle, Isabelle Le Guellec, Sophie Chevreau, Christine Published in Pharmacogenomics (01.09.2013)

“...We describe here the case of a 60-year old male patient treated for an extensive local progression of a pleiomorphic sarcoma on the right tibial crest with...”

Journal Article

Dexamethasone as a probe for docetaxel clearance

by Puisset, Florent Chatelut, Etienne Dalenc, Florence Busi, Florent Cresteil, Thierry Azéma, Joëlle Poublanc, Muriel Hennebelle, Isabelle Lafont, Thierry Chevreau, Christine Roché, Henri Published in Cancer chemotherapy and pharmacology (01.09.2004)

“...A pilot study was conducted in 23 patients in order to assess the correlation between docetaxel clearance (CL) and pharmacokinetics of dexamethasone...”

Fulltext

Journal Article

Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer

by Peggy Gandia Cecile Arellano Quentin Chalret du Rieu Isabelle Lochon Mario Campone Jean-Yves Pierga Muriel Poublanc Isabelle Hennebelle Thomas Filleron Etienne Chatelut Jean-Pierre Delord Published in Current clinical pharmacology (01.11.2011)

“...Background: This study was a multi-centre, dose-escalation trial in patients with advanced cancers. Primary objective was to determine maximum tolerated dose...”

Journal Article

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

by Thomas, Fabienne Rochaix, Philippe White-Koning, Melanie Hennebelle, Isabelle Sarini, Jérôme Benlyazid, Adil Malard, Laurence Lefebvre, Jean-Louis Chatelut, Etienne Delord, Jean Pierre Published in European journal of cancer (1990) (2009)

“...Abstract A clinical study was conducted to determine the safety and efficacy of neoadjuvant erlotinib treatment in patients with head and neck squamous cell...”

Journal Article

Hospicells (ascites‐derived stromal cells) promote tumorigenicity and angiogenesis

by Pasquet, Marlene Golzio, Muriel Mery, Eliane Rafii, Arash Benabbou, Nadia Mirshahi, Pezhman Hennebelle, Isabelle Bourin, Philippe Allal, Ben Teissie, Justin Mirshahi, Massoud Couderc, Bettina Published in International journal of cancer (01.05.2010)

“...The microenvironment is known to play a dominant role in cancer progression. Cells closely associated with tumoral cells, named hospicells, have been recently...”

Fulltext

Journal Article

Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children

by WHITE-KONING, Melanie CIVADE, Elodie GEOERGER, Birgit THOMAS, Fabienne LE DELEY, Marie-Cécile HENNEBELLE, Isabelle DELORD, Jean-Pierre CHATELUT, Etienne VASSAL, Gilles Published in Clinical cancer research (2011)

“...The aim of this pharmacokinetic-pharmacodynamic (PK-PD) analysis was to evaluate the pharmacologic characteristics of erlotinib and its main metabolite...”

Fulltext

Journal Article

Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rareABCC2polymorphism: a case report

by Laurenty, Anne-Pascale Thomas, Fabienne Chatelut, Etienne Bétrian, Sarah Guellec, Chantal Le Hennebelle, Isabelle Guellec, Sophie Le Chevreau, Christine Published in Pharmacogenomics (01.09.2013)

Journal Article

Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare

by Laurenty, Anne-Pascale Thomas, Fabienne Chatelut, Etienne Bétrian, Sarah Guellec, Chantal Le Hennebelle, Isabelle Guellec, Sophie Le Chevreau, Christine Published in Pharmacogenomics (01.09.2013)

“...We describe here the case of a 60-year old male patient treated for an extensive local progression of a pleiomorphic sarcoma on the right tibial crest with...”

Journal Article

Mise en place d’une filière d’élimination des déchets cytotoxiques au CHU et oncopôle de Toulouse

by Metais, Maguy Macovei, Dana Hennebelle, Isabelle Cretu, Yann Marpinard, Monique Levant-Herin, Aude Soulat, Jean-Marc Published in Archives des maladies professionnelles et de l'environnement (01.05.2018)

“...Dans la continuité des recommandations pour la manipulation des cytotoxiques débutées en 2013, la dernière étape est constituée par l’élimination des déchets...”

Journal Article

Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line

by Guichard, Sylvie Hennebelle, Isabelle Bugat, Roland Canal, Pierre Published in Biochemical pharmacology (1998)

“...CPT-11 (irinotecan) is a DNA topoisomerase I inhibitor active against metastatic colorectal carcinoma. We investigated, in a human colon carcinoma cell line,...”

Journal Article

Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo

by Guichard, Sylvie Cussac, Daniel Hennebelle, Isabelle Bugat, Roland Canal, Pierre Published in International journal of cancer (27.11.1997)

“...Irinotecan, a DNA‐topoisomerase‐I inhibitor, is active against metastatic colon carcinoma. We investigated the effects of irinotecan and 5FU combinations in...”

Fulltext

Journal Article

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft : Pharmacokinetic and pharmacodynamic evaluation

by GUICHARD, Sylvie MONTAZERI, Ashraf CHATELUT, Etienne HENNEBELLE, Isabelle BUGAT, Roland CANAL, Pierre Published in Clinical cancer research (2001)

“...Topotecan is a topoisomerase (Topo) I inhibitor used in ovarian carcinoma chemotherapy. Topo I inhibitors are thought to be more cytotoxic using protracted...”

Journal Article

Contribution of apoptosis in the cytotoxicity of the oxaliplatin–irinotecan combination in the HT29 human colon adenocarcinoma cell line

by Arnould, Stéphanie Guichard, Sylvie Hennebelle, Isabelle Cassar, Georges Bugat, Roland Canal, Pierre Published in Biochemical pharmacology (2002)

“...Interactions between the topoisomerase I inhibitor irinotecan (CPT-11) and the platinum derivative oxaliplatin (L-OHP) were investigated in HT29 colon cancer...”

Journal Article

Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

by Guichard, Sylvie Arnould, Stéphanie Hennebelle, Isabelle Bugat, Roland Canal, Pierre Published in Anti-cancer drugs (01.10.2001)

“...The in vitro and in vivo combination of oxaliplatin and irinotecan was investigated in a panel of four human colon cancer cell lines and their counterpart...”

Fulltext

Journal Article

Élaboration de recommandations pour la manipulation des médicaments cytotoxiques par les salariés du CHU et du futur oncopôle de Toulouse en vue d’harmoniser les pratiques professi...

by Macovei, Dana Metais, Maguy Levant-Herin, Aude Hennebelle, Isabelle Portes, Éric Cretu, Yann Vinson, Camille Canonge, Jean-Marie Somme, Jérémie Marpinard, Monique Descazaux, Thomas Soulat, Jean-Marc Herin, Fabrice Published in Archives des maladies professionnelles et de l'environnement (01.06.2016)

“...Ce travail a consisté à mener, par une approche pluridisciplinaire et participative, une démarche de prévention collective des risques liés aux cytotoxiques à...”

Journal Article

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5‐fluorouracil‐based therapy together with cetuximab–irinotecan

by Etienne‐Grimaldi, Marie‐Christine Bennouna, Jaafar Formento, Jean‐Louis Douillard, Jean‐Yves Francoual, Mireille Hennebelle, Isabelle Chatelut, Etienne Francois, Eric Faroux, Roger El Hannani, Chaza Jacob, Jacques‐Henri Milano, Gérard Published in British journal of clinical pharmacology (01.05.2012)

“...WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Previous pharmacogenetic studies have reported the potential predictive value of thymidylate synthase (TYMS)...”

Fulltext

Journal Article

Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft

by Sylvie Guichard Ashraf Montazeri Etienne Chatelut Isabelle Hennebelle Roland Bugat Pierre Canal Published in Clinical cancer research (01.10.2001)

“...Topotecan is a topoisomerase (Topo) I inhibitor used in ovarian carcinoma chemotherapy. Topo I inhibitors are thought to be more cytotoxic using protracted...”

Narrow search